Quotient (QTNTQ) 10-K 30 May 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2018	May 29, 2018	Sep. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	QTNT
Entity Registrant Name	Quotient Ltd
Entity Central Index Key	1,596,946
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 135.4
Entity Common Stock, Shares Outstanding		45,755,978

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Current assets:
Cash and cash equivalents	$ 20,165	$ 4,754
Short-term investments	5,669	16,057
Trade accounts receivable, net	2,862	2,556
Inventories	16,278	13,636
Prepaid expenses and other current assets	7,065	3,629
Total current assets	52,039	40,632
Cash reserve account	5,040	5,040
Property and equipment, net	60,156	63,530
Intangible assets, net	914	769
Deferred income taxes	649
Other non-current assets	5,043
Total assets	123,841	109,971
Current liabilities:
Accounts payable	5,441	10,782
Accrued compensation and benefits	5,312	3,641
Accrued expenses and other current liabilities	15,340	13,509
Current portion of lease incentive	443	422
Current portion of capital lease obligation	515	1,374
Total current liabilities	27,051	29,728
Long-term debt	85,063	80,704
Lease incentive, less current portion	443	844
Capital lease obligation, less current portion	1,422	174
Defined benefit pension plan obligation	6,168	5,337
Total liabilities	138,472	134,062
Commitments and contingencies
Shareholders' equity (deficit)
Additional paid in capital	23,708	15,885
Accumulated other comprehensive loss	(16,634)	(19,292)
Accumulated deficit	(275,639)	(193,301)
Total shareholders' deficit	(14,631)	(24,091)
Total liabilities and shareholders' deficit	123,841	109,971
7% Cumulative Redeemable Preference Shares [Member]
Current liabilities:
Preferred stock value	18,325	17,275
Ordinary Shares [Member]
Shareholders' equity (deficit)
Common stock value	$ 253,934	$ 172,617

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Common stock, par value
Common stock, shares issued	45,646,424	29,567,698
Common stock, shares outstanding	45,646,424	29,567,698
7% Cumulative Redeemable Preference Shares [Member]
Dividend percentage	7.00%	7.00%

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product sales	$ 23,913	$ 20,127	$ 18,022
Other revenues	819	2,100	500
Total revenue	24,732	22,227	18,522
Cost of revenue	(10,471)	(10,844)	(9,658)
Gross profit	14,261	11,383	8,864
Operating expenses:
Sales and marketing	(7,347)	(5,660)	(3,073)
Research and development, net of government grants	(51,202)	(57,064)	(28,781)
General and administrative expense:
Compensation expense in respect of share options and management equity incentives	(4,156)	(4,221)	(2,004)
Other general and administrative expenses	(21,544)	(18,497)	(24,094)
Total general and administrative expense	(25,700)	(22,718)	(26,098)
Total operating expense	(84,249)	(85,442)	(57,952)
Operating loss	(69,988)	(74,059)	(49,088)
Other income (expense):
Interest expense, net	(15,365)	(9,903)	(4,151)
Change in financial liability for share warrants			15,857
Other, net	2,366	(1,107)	3,504
Other income (expense), net	(12,999)	(11,010)	15,210
Loss before income taxes	(82,987)	(85,069)	(33,878)
Provision for income taxes	649
Net loss	(82,338)	(85,069)	(33,878)
Other comprehensive income (loss):
Change in fair value of effective portion of foreign currency cash flow hedges	305	(63)	9
Unrealized gain on short-term investments	6	19
Foreign currency gain (loss)	2,240	(6,215)	(3,028)
Provision for pension benefit obligation	107	(410)	(4,502)
Other comprehensive loss, net	2,658	(6,669)	(7,521)
Comprehensive loss	(79,680)	(91,738)	(41,399)
Net loss available to ordinary shareholders - basic and diluted	$ (82,338)	$ (85,069)	$ (33,878)
Loss per share - basic and diluted	$ (2.02)	$ (3.02)	$ (1.73)
Weighted-average shares outstanding - basic and diluted	40,839,309	28,145,472	19,558,152

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Ordinary Shares [Member]	Additional paid in (Distribution in Excess of) Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Beginning balance at Mar. 31, 2015	$ (1,615)	$ 84,525	$ (6,684)	$ (5,102)	$ (74,354)
Beginning balance, Shares at Mar. 31, 2015		17,020,574
Issue of shares, net of issue costs, Amount	36,835	$ 36,835
Issue of shares, net of issue costs, Shares		4,444,445
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	41	$ 41
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		21,212
Issue of shares upon exercise of warrants, Amount	49,667	$ 34,513	15,154
Issue of shares upon exercise of warrants, Shares		3,922,719
Issue of warrants	1,190		1,190
Net loss	(33,878)				(33,878)
Change in the fair value of the effective portion of foreign currency cash flow hedges	9			9
Foreign currency gain (loss) on:
Foreign currency translation loss/Retranslation of foreign entities	(3,028)			(3,028)
Provision for pension benefit obligation	(4,502)			(4,502)
Other comprehensive loss, net	(7,521)			(7,521)
Stock-based compensation	2,004		2,004
Ending balance at Mar. 31, 2016	46,723	$ 155,914	11,664	(12,623)	(108,232)
Ending balance, Shares at Mar. 31, 2016		25,408,950
Issue of shares, net of issue costs, Amount	16,682	$ 16,682
Issue of shares, net of issue costs, Shares		3,270,000
Exercise of pre-funded warrants, Amount	9	$ 9
Exercise of pre funded warrants, Shares		850,000
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	12	$ 12
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		38,748
Net loss	(85,069)				(85,069)
Change in the fair value of the effective portion of foreign currency cash flow hedges	(63)			(63)
Unrealized gain on short-term investments	19			19
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	6,747			6,747
Foreign currency translation loss/Retranslation of foreign entities	(12,962)			(12,962)
Provision for pension benefit obligation	(410)			(410)
Other comprehensive loss, net	(6,669)			(6,669)
Stock-based compensation	4,221		4,221
Ending balance at Mar. 31, 2017	$ (24,091)	$ 172,617	15,885	(19,292)	(193,301)
Ending balance, Shares at Mar. 31, 2017	29,567,698	29,567,698
Issue of shares, net of issue costs, Amount	$ 81,206	$ 81,206
Issue of shares, net of issue costs, Shares		15,914,683
Issue of shares upon exercise of incentive share options and vesting of RSU's, Amount	111	$ 111
Issue of shares upon exercise of incentive share options and vesting of RSU's, Shares		164,043
Issue of warrants	3,667		3,667
Net loss	(82,338)				(82,338)
Change in the fair value of the effective portion of foreign currency cash flow hedges	305			305
Unrealized gain on short-term investments	6			6
Foreign currency gain (loss) on:
Long-term investment nature intra-entity balances	(9,105)			(9,105)
Foreign currency translation loss/Retranslation of foreign entities	11,345			11,345
Provision for pension benefit obligation	107			107
Other comprehensive loss, net	2,658			2,658
Stock-based compensation	4,156		4,156
Ending balance at Mar. 31, 2018	$ (14,631)	$ 253,934	$ 23,708	$ (16,634)	$ (275,639)
Ending balance, Shares at Mar. 31, 2018	45,646,424	45,646,424

CONSOLIDATED STATEMENTS OF CHA6

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Statement Of Stockholders Equity [Abstract]
Issue of shares, issue costs	$ 680	$ 1,348	$ 3,165

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
OPERATING ACTIVITIES:
Net loss	$ (82,338)	$ (85,069)	$ (33,878)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and loss on disposal of fixed assets	10,405	9,461	2,945
Share-based compensation	4,156	4,221	2,004
Amortization of lease incentive	(435)	(428)	(434)
Swiss pension obligation	659	616
Amortization of deferred debt issue costs	4,359	6,774	1,472
Accrued preference share dividends	1,050	1,050	1,050
Deferred income taxes	(649)
Change in financial liability for share warrants			(15,857)
Net change in assets and liabilities:
Trade accounts receivable, net	(87)	(584)	(519)
Inventories	(1,741)	(1,766)	(8,126)
Accounts payable and accrued liabilities	(3,310)	9,960	955
Accrued compensation and benefits	1,596	778	812
Other assets	(2,083)	(1,213)	2,603
Net cash used in operating activities	(68,418)	(56,200)	(46,973)
INVESTING ACTIVITIES:
Increase in short-term investments	(78,000)	(30,009)
Realization of short-term investments	88,395	13,971
Purchase of property and equipment	(21,604)	(20,155)	(28,906)
Sale of property and equipment	19,741
Payment of rent deposit	(5,043)
Purchase of intangible assets	(150)	(71)	(71)
Net cash from (used in) investing activities	3,339	(36,264)	(28,977)
FINANCING ACTIVITIES:
Repayment of finance leases	(1,692)	(141)	(39)
Proceeds from drawdown of new debt		84,000	15,500
Repayment of debt		(33,450)	(500)
Debt issue costs		(5,530)	(703)
Increase in cash reserve account		(5,040)
Proceeds from issuance of ordinary shares and warrants	84,984	16,703	71,390
Net cash generated from financing activities	83,292	56,542	85,648
Effect of exchange rate fluctuations on cash and cash equivalents	(2,802)	(3,424)	(3,123)
Change in cash and cash equivalents	15,411	(39,346)	6,575
Beginning cash and cash equivalents	4,754	44,100	37,525
Ending cash and cash equivalents	20,165	4,754	44,100
Supplemental cash flow disclosures:
Interest paid	$ 10,144	$ 1,702	$ 2,164

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies Organization and Business The principal activity of Quotient Limited and its subsidiaries (the “Group” and or the “Company”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide. From its incorporation in 2012 to March 31, 2017, the Company has raised $70.6 million of gross proceeds through the private placement of its ordinary and preference shares and warrants, $132.8 million of gross proceeds from public offerings of its shares and issuances of ordinary shares upon exercise of warrants and $84.0 million of gross proceeds from the issuance of 12% Senior Secured Notes (“the Secured Notes”). During the fiscal year ended March 31, 2018, on April 10, 2017, the Company completed a public offering of 8,050,000 newly issued ordinary shares at a price of $6.00 per share which raised $48.3 million of gross proceeds before underwriting discounts and other offering expenses. On October 24, 2017, the Company entered into subscription agreements for the private placement of (i) 7,864,683 newly issued ordinary shares at a subscription price of $4.64 per share, (ii) newly issued warrants, at a purchase price of $0.125 per underlying warrant share, exercisable for up to 8,414,683 ordinary shares at an exercise price of $5.80 per ordinary share, and (iii) newly issued pre-funded warrants, at a purchase price of $4.755 per underlying pre-funded warrant share, exercisable for up to 550,000 ordinary shares at an exercise price of $0.01 per ordinary share. The aggregate gross proceeds were $40.2 million. If the warrants are exercised in full prior to their expiration on July 31, 2018, it would result in additional proceeds of $48.8 million. However, there can be no assurance that the warrants will be exercised. The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $275.6 million as of March 31, 2018. At March 31, 2018, the Company had available cash holdings and short-term investments of $25.5 million. to obtain adequate financing when necessary and the terms of any financings may not be advantageous to the Company and may result in dilution to its Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. All gains and losses realized from foreign currency transactions denominated in currencies other than the foreign subsidiary’s functional currency are included in foreign currency exchange gain (loss) as part of other income or expenses in the Consolidated Statements of Comprehensive Loss. Adjustments resulting from translating the financial statements of all foreign subsidiaries into U.S. dollars are reported as a separate component of accumulated other comprehensive loss and changes in shareholders’ deficit. The assets and liabilities of the Company’s foreign subsidiaries are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at rates approximating the weighted average rates during the period. The translation effects of inter-company loans designated as long term net investments in subsidiaries are included in accumulated other comprehensive loss. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 4, “Fair Value Measurements,” for information and related disclosures regarding our fair value measurements. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of March 31, 2018 and 2017, all cash and cash equivalents comprised cash balances held with the banks used by the Company and its subsidiaries. At March 31, 2018 and March 31, 2017, the Company held $320 and $305 respectively in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary and $5.0 million in a cash reserve account pursuant to the indenture governing the Secured Notes. The cash reserve account is classified as a long- term asset as the indenture requires it to be maintained while the Secured Notes remain outstanding. Short-term Investments Short-term investments represent investments in a money-market fund which is valued daily and which has no minimum notice period for withdrawals. The fund is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company records the value of its investment in the fund based on the quoted value of the fund at the balance sheet date. Unrealized gains or losses are recorded in accumulated other comprehensive loss and are transferred to the statement of comprehensive loss when they are realized. Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as general and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. The allowance for doubtful accounts at March 31, 2018 and 2017 was $93 and $103, respectively. Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting of foreign exchange contracts and short-term investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the foreign exchange contracts consist of large financial institutions of high credit standing. The short-term investments are invested in a fund which is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company’s main financial institutions for banking operation held all of the Company’s cash and cash equivalents as of March 31, 2018 and March 31, 2017. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of March 31, 2018 and March 31, 2017. This customer represented 51% and 59% of the accounts receivable balances, as of March 31, 2018 and March 31, 2017, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the fiscal years ended March 31, 2018, 2017 and 2016. This customer represented 63%, 60% and 57% of total product sales for the fiscal years March 31, 2018, 2017 and 2016, respectively. Inventory Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of March 31, 2018 and 2017. Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: • Land—not depreciated. • Plant, machinery and equipment—4 to 25 years; • Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparing the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the fiscal years ended March 31, 2018, 2017 and 2016, no impairment losses have been recorded. Intangible Assets and Goodwill Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles—7 years The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. No impairment losses have been recorded in any of the years ended March 31, 2018, 2017 or 2016. Goodwill represents the excess of the purchase price in a business combination over the fair value of tangible and identifiable intangible assets acquired less liabilities assumed. Goodwill resulting from a business combination in 2007 has been fully impaired. Revenue Recognition The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract and included in other revenues. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. Pursuant to the Umbrella Supply Agreement with Ortho-Clinical Diagnostics (“Ortho”), in June 2013, the Company executed a product attachment relating to the development of a range of rare antisera products. This product attachment was amended in August 2016. During the year ended March 31, 2017, the Company recognized the milestones of $1,300 related to the completion of the CE marking of the products for use on Ortho’s automation platforms and $800 related to the receipt of FDA approval of certain of the rare antisera products. The Company earned a milestone of $600 related to the receipt of FDA approval of the rare antisera products in the year ended March 31, 2018 and, under the terms of the amended product attachment, the Company is entitled to receive a milestone payment of $1,500 upon the updating of the FDA approvals to cover use of the products on Ortho’s automation platforms. In January 2015, the Company entered into a supply and distribution agreement with Ortho related to the commercialization and distribution of certain MosaiQ The Company has concluded that as each of these milestones require significant levels of development work to be undertaken and there was no certainty at the start of the projects that the development work would be successful, these milestones are substantive and should be accounted for under the milestone method of revenue recognition. Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. Other than materials assessed as having alternative future uses and which are recognized as prepaid expenses, the Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense. Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Comprehensive Loss. In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach for share options and a barrier option pricing model for multi-year performance based restricted share units or MRSUs, both of which require the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their awards before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to awards that will ultimately not complete their vesting requirements (forfeitures). Where modifications are made to vesting conditions, as happened during the year ended March 31, 2018 upon the retirement of Paul Cowan, the Company's former Chief Executive Officer, the Company considers the nature of the change and accounts for the change in accordance with ASC 715 Compensation – Stock Compensation Share Warrants The Company has three classes of warrants to purchase ordinary shares outstanding: (i) warrants that were issued in December 2013 and August 2015 in connection with the entry into and subsequent amendment of the Company’s then existing secured term loan facility; (ii) warrants issued in October 2017 as part of a private placement of ordinary shares and warrants, and (iii) pre-funded warrants issued in October 2017 as part of the private placement of ordinary shares and warrants. None of these warrants contain any obligation to transfer value and, as such, the issuance of these warrants has been recorded in additional paid in capital as part of shareholders’ equity. The Company also issued warrants to purchase ordinary shares at the time of its initial public offering. These warrants were recorded as a liability because the underlying terms of the warrants contained provisions that may have obligated the Company to transfer value in certain circumstances. The warrants were recorded at fair value upon issuance and were subject to re-measurement to fair value at each balance sheet date, with any change in fair value recognized as component of other income (expense), net on the Consolidated Statements of Comprehensive Loss. These warrants expired on October 26, 2015 and were either exercised prior to that date or expired on that date. As a result, at March 31, 2018 and March 31, 2017, there was no longer any liability related to these warrants. Leases At the inception of each lease, the Company reviews the terms of the lease in accordance with ASC 840 Leases Rentals relating to operating leases are expensed over the life of the lease. Derivative Financial Instruments In the normal course of business, the Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations. The Company’s policy is to mitigate the effect of these exchange rate fluctuations on certain foreign currency denominated business exposures. The Company has a policy that allows the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on forecasted revenue denominated in foreign currencies. The Company carries derivative financial instruments (derivatives) on the balance sheet at their fair values. The Company does not use derivatives for trading or speculative purposes. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. To hedge foreign currency risks, the Company uses foreign currency exchange forward contracts, where possible and prudent. These forward contracts are valued using standard valuation formulas with assumptions about future foreign currency exchange rates derived from existing exchange rates, interest rates, and other market factors. The Company considers its most current forecast in determining the level of foreign currency denominated revenue to hedge as cash flow hedges. The Company combines these forecasts with historical trends to establish the portion of its expected volume to be hedged. The revenue and expenses are hedged and designated as cash flow hedges to protect the Company from exposures to fluctuations in foreign currency exchange rates. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, the related hedge gains and losses on the cash flow hedge are reclassified from accumulated other comprehensive loss to the consolidated statement of comprehensive loss at that time. Income Taxes The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets. Pension Obligation The Company maintains a pension plan covering employees in Switzerland pursuant to the requirements of Swiss pension law. Certain aspects of the plan require that it be accounted for as a defined benefit plan pursuant to ASC 715 Compensation – Retirement Benefits The Company uses an actuarial valuation to determine its pension benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Details of the assumptions used to determine the net funded status are set out in Note 11. The Company’s pension plan assets are assigned to their respective levels in the fair value hierarchy in accordance with the valuation principles described in the ‘‘Fair Value of Financial Instruments’’ section above. Debt Issuance Costs and Royalty Rights The Company follows the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. The royalty rights agreements entered into with subscribers to the issue of the Secured Notes are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 “ Debt” Adoption of New Accounting Standards The FASB issued ASU 2014-09, Revenue from Contracts with Customers Recent Accounting Pronouncements Not Yet Adopted The FASB issued ASU 2016-02, Leases The FASB issued ASU 2016-18, Statement of Cash Flows - Restricted Cash The FASB issued ASU 2017-07, Compensation - Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost The FASB issued ASU 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 2. Intangible Assets March 31, 2018 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,758 $ (2,758 ) $ — — Brands associated with acquired cell lines 569 (150 ) 419 29.5 years Product licenses 954 (459 ) 495 5.2 years Other intangibles 179 (179 ) — — Total $ 4,460 $ (3,546 ) $ 914 16.3 years March 31, 2017 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,458 $ (2,458 ) $ — — Brands associated with acquired cell lines 507 (121 ) 386 30.4 years Product licenses 716 (333 ) 383 5.4 years Other intangibles 160 (160 ) — — Total $ 3,841 $ (3,072 ) $ 769 17.9 years Amortization expense was $94, $73, and $89 in financial years 2018, 2017, and 2016, respectively. Total future amortization expense for intangible assets that have definite lives, based upon the Company’s existing intangible assets and their current estimated useful lives as of March 31, 2018, is estimated as follows: 2019 $ 110 2020 110 2021 110 2022 110 2023 110 Thereafter 364 Total $ 914

Debt

Debt	12 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt	Note 3. Debt Long-term debt comprises: March 31, 2018 March 31, 2017 Total debt $ 84,000 $ 84,000 Less current portion — — Long-term debt $ 84,000 $ 84,000 Deferred debt costs and royalty liability, net of amortization 1,063 (3,296 ) $ 85,063 $ 80,704 The Company’s debt at March 31, 2018 and March 31, 2017 comprises the 12% Senior Secured Notes due 2023 issued on October 14, 2016. On that date, the Company completed the private placement of up to $120 million aggregate principal amount of the Secured Notes and entered into an indenture with the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent. The obligations of the Company under the indenture and the Secured Notes are unconditionally guaranteed on a secured basis by the guarantors, which include all the Company’s subsidiaries, and the indenture contains customary events of default. The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent. Upon the occurrence of a Change of Control, subject to certain conditions, or certain Asset Sales (each, as defined in the indenture), holders of the Secured Notes may require the Company to repurchase for cash all or part of their Secured Notes at a repurchase price equal to 101% or 100%, respectively, of the principal amount of the Secured Notes to be repurchased, plus accrued and unpaid interest to the date of repurchase. The Company issued $84 million aggregate principal amount of the Secured Notes on October 14, 2016 and, so long as no event of default has occurred, the Company will issue an additional $36 million aggregate principal amount of the Secured Notes upon public announcement of field trial results for the MosaiQ IH Microarray that demonstrates greater than 99% concordance for the detection of blood group antigens and greater than 95% concordance for the detection of blood group antibodies when compared to predicate technologies for a pre-defined set of blood group antigens and antibodies. The Company paid $5 million of the net proceeds into the cash reserve account maintained with the collateral agent under the terms of the indenture. Interest on the Secured Notes accrues at a rate of 12% per annum and is payable semi-annually on April 15 and October 15 of each year. Commencing on April 15, 2019, the Company will also pay an installment of principal of the Secured Notes on each April 15 and October 15 until October 15, 2023 pursuant to a fixed amortization schedule. In connection with the offering on October 14, 2016, the Company entered into royalty rights agreements, pursuant to which the Company sold to the note purchasers in the offering, the right to receive an aggregate payment equal to 2.0% of the aggregate net sales of MosaiQ Instruments and MosaiQ Microarrays made in the donor testing market in the United States and the European Union. The royalty will be payable beginning on the date that the Company or its affiliates enters into a contract for the sale of Instruments or MosaiQ Microarrays in the donor testing market in the European Union or the United States and will end on the last day of the calendar quarter in which the eighth anniversary of the first contract date occurs Debt” The outstanding debt at March 31, 2018 falls due for repayment as follows: Within 1 year $ — Between 1 and 2 years 13,440 Between 2 and 3 years 14,280 Between 3 and 4 years 16,800 Between 4 and 5 years 18,480 After 5 years 21,000 Total debt $ 84,000

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements Assets and liabilities measured and recorded at fair value on a recurring basis The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: March 31, 2018 Level 1 Level 2 Level 3 Total Assets: Pension plan assets (1) $ — $ 9,616 $ — $ 9,616 Short-term investments (2) 5,669 — — 5,669 Foreign currency forward contracts (3) — 118 — 118 Total assets measured at fair value $ 5,669 $ 9,734 $ — $ 15,403 March 31, 2018 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts (3) $ — $ 64 $ — $ 64 Total liabilities measured at fair value $ — $ 64 $ — $ 64 March 31, 2017 Level 1 Level 2 Level 3 Total Assets: Pension plan assets (1) $ — $ 7,981 $ — $ 7,981 Short-term investments (2) 16,057 — — 16,057 Total assets measured at fair value $ 16,057 $ 7,981 $ — $ 24,038 March 31, 2017 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts (3) $ — $ 252 $ — $ 252 Total liabilities measured at fair value $ — $ 252 $ — $ 252 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the Swiss Life collective investment fund. (2) The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”. (3) The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	12 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Consolidated Balance Sheet Detail	Note 5. Inventory The following table summarizes inventory by category for the periods presented: March 31, 2018 March 31, 2017 Raw materials $ 10,024 $ 8,993 Work in progress 4,226 3,260 Finished goods 2,028 1,383 Total inventories $ 16,278 $ 13,636 Inventory at March 31, 2018 included $8,441 of raw materials, $1,528 of work in progress, and $389 of finished products related to the MosaiQ project. Inventory at March 31, 2017 included $7,659 of raw materials and $1,415 of work in progress related to the MosaiQ project. Property and equipment The following table summarizes property and equipment by categories for the periods presented: March 31, 2018 March 31, 2017 Land $ — $ 1,286 Plant and equipment 51,912 44,797 Leasehold improvements 34,611 32,343 Total property and equipment 86,523 78,426 Less: accumulated depreciation (26,367 ) (14,896 ) Total property and equipment, net $ 60,156 $ 63,530 Depreciation expenses were $10,311, $9,375 and $2,856 in financial years 2018, 2017, and 2016, respectively. Accrued compensation and benefits Accrued compensation and benefits consist of the following: March 31, 2018 March 31, 2017 Salary and related benefits $ 455 $ 403 Accrued vacation 504 413 Accrued payroll taxes 1,353 325 Accrued incentive payments 3,000 2,500 Total accrued compensation and benefits $ 5,312 $ 3,641 Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: March 31, 2018 March 31, 2017 Accrued legal and professional fees $ 280 $ 449 Accrued interest 4,612 4,640 Goods received not invoiced 1,272 932 Accrued capital expenditure 3,309 1,387 Accrued development expenditure — 4,187 Other accrued expenses 5,867 1,914 Total accrued expenses and other current liabilities $ 15,340 $ 13,509 At March 31, 2018, other accrued expenses included a value added tax liability of $2,905 related to the completion of the sale of the Company’s new conventional reagents manufacturing facility (the “Biocampus facility”) in March 2018. There was an offsetting value added tax recoverable balance within prepaid expenses and other current assets at March 31, 2018. There were no equivalent amounts at March 31, 2017.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Lease commitments The Company leases its facilities and certain equipment under operating leases that expire at various dates through 2052. Some of the leases contain renewal options, escalation clauses, rent concessions, and leasehold improvement incentives. Rent expense is recognized on a straight-line basis over the lease term. Rent expense was $3,063, $2,928 and $2,923 in financial years ended March 31, 2018, 2017 and 2016, respectively. The following is a schedule by years of minimum future rentals on non-cancelable operating leases as of March 31, 2018: 2019 $ 3,828 2020 3,477 2021 1,889 2022 1,923 2023 1,976 Thereafter 80,919 Total minimum future lease payments $ 94,012 Sale-leaseback transaction During the year ended March 31, 2018, the Company completed a sale-leaseback transaction and sold the Biocampus facility, but retained a leasehold interest as tenant of the property. The transaction resulted in net cash proceeds of $19,741 and a gain of $473 which has been deferred and recorded within accrued liabilities on the Consolidated Balance Sheet and will be amortized on a straight-line basis over the lease term as a reduction of the rental expense in the consolidated statements of comprehensive loss. Additionally, the lease required the Company to provide a rental deposit of $5,043 at March 31, 2018 which is included within other non-current assets in the March 31, 2018 Consolidated Balance Sheet. The Company evaluated the transaction in accordance with ASC 840, Leases Lease commitments The Company has entered into capital leases for the purchase of equipment that has a gross cost and net book value of $3,130 and $2,810, respectively as of March 31, 2018 and $1,928 and $1,663, respectively as of March 31, 2017. The following is a schedule of future annual repayments on capital leases as of March 31, 2018: 2019 $ 515 2020 510 2021 392 2022 321 2023 199 Thereafter — Total minimum future lease payments $ 1,937 Purchase obligations The Company has purchase obligations that are associated with agreements for purchases of goods or services. Management believes that cancellation of these contracts is unlikely and thus the Company expects to make future cash payments according to the contract terms. The following is a schedule by years of purchase obligations as of March 31, 2018: 2019 $ 15,083 2020 9,200 2021 22,155 2022 18,267 2023 8,591 Thereafter 9,767 Total minimum future purchase obligations $ 83,063 Government Grant In 2008, the Company was awarded research and development grant funding from Scottish Enterprise amounting to £1,791 for the development of MosaiQ. The total grant claimed to March 31, 2018 is £1,790. Regular meetings are held to update Scottish Enterprise with the status of the project and whilst the terms of the grant award provide for full repayment of the grant in certain circumstances, the Company does not consider that any repayment is likely. Hedging arrangements The Company’s subsidiary in the United Kingdom (“UK”) has entered into three foreign currency forward contracts to sell $500 and purchase pounds sterling at a rate of £1:$1.2990 in each calendar month through June 2018 as hedges of its U.S. dollar denominated revenues. The fair value of these contracts at March 31, 2018 was an asset of $118. The same subsidiary also had six contracts to sell $500 in each calendar month from July 2018 through December 2018 at £1:$1.4315 as hedges of its U.S. dollar denominated revenues. The fair values of these contracts, and similar contracts in place at March 31, 2017, amounted to liabilities of $64 and $252 at March 31, 2018 and March 31, 2017, respectively. The foreign currency forward contracts were entered into to mitigate the foreign exchange risk arising from the fluctuations in the value of U.S. dollar denominated transactions entered into by our UK subsidiary. These foreign currency forward contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive loss and subsequently recognized in revenue/expense in the same period the hedged items are recognized. At inception and at each quarter end, hedges are tested prospectively and retrospectively for effectiveness. Changes in the fair value of foreign currency forward contracts due to changes in time value are excluded from the assessment of effectiveness and are recognized in revenue in the current period. The change in time value related to these contracts was not material for all reported periods. To qualify for hedge accounting, the hedge relationship must meet criteria relating both to the derivative instrument and the hedged item. These criteria include identification of the hedging instrument, the hedged item, the nature of the risk being hedged and how the hedging instrument’s effectiveness in offsetting the exposure to changes in the hedged item’s cash flows will be measured. There were no gains or losses during the years ended March 31, 2018, March 31, 2017 or March 31, 2016 associated with ineffectiveness or forecasted transactions that failed to occur. To receive hedge accounting treatment, hedging relationships are formally documented at the inception of the hedge and the hedges must be tested to demonstrate an expectation of providing highly effective offsetting changes to future cash flows on hedged transactions.

Geographic Information

Geographic Information	12 Months Ended
	Mar. 31, 2018
Geographic Areas Revenues And Long Lived Assets [Abstract]
Geographic Information	Note 7. Geographic Information The Company operates in one business segment. Revenues are attributed to countries based on the location of the Company’s channel partners as well as direct customers. The following table represents revenue attributed to countries based on the location of the customer: Year ended March 31, 2018 2017 2016 Revenue: United States $ 12,917 $ 11,432 $ 8,879 United Kingdom 980 1,003 1,437 France 5,608 4,733 3,376 Japan 3,335 3,141 2,836 Other foreign countries (1) 1,892 1,918 1,994 $ 24,732 $ 22,227 $ 18,522 (1) No individual country represented more than 10% of the respective totals. The table below lists the Company’s property and equipment, net of accumulated depreciation, by country. With the exception of property and equipment, the Company does not identify or allocate its assets by geographic area: March 31, 2018 March 31, 2017 Long-lived assets: United Kingdom $ 24,141 $ 20,925 Switzerland 36,009 42,596 United States 6 9 $ 60,156 $ 63,530 Other income (expense), net includes foreign exchange gains and losses arising on the settlement of transactions in currencies other than the functional currencies of the entity concerned and from retranslation of assets and liabilities denominated in foreign currencies at period end rates. In the years ended March 31, 2018, March 31, 2017 and March 31, 2016, the respective amounts were gains of $2,366, $2,853 and $4,120.

Ordinary and Preference Shares

Ordinary and Preference Shares	12 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Ordinary and Preference Shares	Note 8. Ordinary shares The Company’s issued and outstanding ordinary shares consist of the following: Shares Issued and Outstanding March 31, 2018 March 31, 2017 Par value Ordinary shares 45,646,424 29,567,698 $ — Total 45,646,424 29,567,698 $ — Preference shares The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share March 31, 2018 March 31, 2017 March 31, 2018 March 31, 2017 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 27.50 $ 25.92 Total 666,665 666,665 The 7% Cumulative Redeemable Preference shares were issued to Ortho-Clinical Diagnostics Finco S.Á.R.L., an affiliate of Ortho on January 29, 2015 at a subscription price of $22.50 per share. These preference shares are redeemable at the request of the shareholder on the “Redemption Trigger Date” which is currently the date of the fifth anniversary of the date of issue of the preference shares, but the Company may extend the redemption date in one year increments up to the tenth anniversary of the date of issue. Because the 7% Cumulative Redeemable Preference shares are redeemable at the option of the shareholders, they are shown as a liability in the Consolidated Balance Sheet.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	Note 9. Share-Based Compensation The Company records share-based compensation expense in respect of options and restricted share units (“RSUs”), including multi-year performance based restricted share units (“MRSUs”), issued under its share incentive plans and in respect of deferred shares issued to employees. Share-based compensation expense amounted to $4,156 in the year ended March 31, 2018, $4,221 in the year ended March 31, 2017 and $2,004 in the year ended March 31, 2016. Option Plans The 2012 Option Plan (the “Option Plan”) was designed in order to grant options on ordinary shares in the capital of the Company to certain of its directors and employees. The purpose of the Option Plan is to provide employees with an opportunity to participate directly in the growth of the value of the Company by receiving options for shares. Each option may be exercised for one ordinary share of the Company. The 2012 Option Plan was approved by the shareholders on February 16, 2012. The total number of shares in respect of which options may be granted under the 2012 Option Plan is limited at 839,509. Options that lapse or are forfeited are available to be granted again. Options generally vest over a period of three years but certain employees have shorter vesting periods. The contractual life of all options is 10 years. Options were not exercisable before the Company became a public company and all outstanding options become exercisable in the event of an acquisition of 75% or more of the share capital of the Company by a third party. No further awards will be granted under the 2012 Option Plan. The 2014 Stock Incentive Plan was approved by the directors and shareholders immediately prior to the Company’s initial public offering in April 2014. The 2014 Plan was designed to provide flexibility to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the business depends, and to provide additional incentives to such persons to devote their effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company and thereby have an interest in its success and increased value. Under the 2014 Plan, 1,500,000 ordinary shares were initially reserved for issuance. This number is subject to adjustment in the event of a recapitalization, share split, share consolidation, reclassification, share dividend or other change in the Company’s capital structure and automatically increases annually on April 1 of each year. The number of shares reserved for issuance under the plan was also increased by 750,000 as a result of a resolution passed at the Annual Shareholder meeting held on October 28, 2016. The plan provides for the issuance of share options, restricted shares, RSUs (including MRSUs) or share appreciation rights (“SARs”). The Company has only issued options, RSUs and MRSUs under the plan prior to March 31, 2018. To the extent that an award terminates, or expires for any reason, then any shares subject to the award may be used again for new grants. However, shares which are (i) not issued or delivered as a result of the net settlement of outstanding SARs or options; (ii) used to pay the exercise price related to outstanding options; (iii) used to pay withholding taxes related to outstanding options or SARs; or (iv) repurchased on the open market with the proceeds from an option exercise, will not be available for grant under the 2014 Plan. Share option activity The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2015 1,208,118 $ 5.58 103 Granted 404,327 14.71 120 Exercised (8,712 ) 4.72 — Forfeited (13,795 ) 10.25 — Outstanding — March 31, 2016 1,589,938 $ 7.86 96 Granted 419,682 9.12 120 Exercised (8,483 ) 1.44 — Forfeited (52,220 ) 12.50 — Outstanding — March 31, 2017 1,948,917 $ 8.04 90 Granted 406,480 6.93 120 Exercised (36,240 ) 3.07 — Forfeited (222,874 ) 9.16 — Outstanding — March 31, 2018 2,096,283 $ 7.79 84 Exercisable —March 31, 2018 1,368,870 $ 7.27 74 The following table summarizes the options granted in the year ended March 31, 2018 with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 24, 2017 305,525 $ 7.58 $ 7.58 $ 4.62 August 9, 2017 4,000 $ 5.41 $ 5.41 $ 3.34 October 31, 2017 67,179 $ 5.21 $ 5.21 $ 3.20 November 1, 2017 925 $ 5.11 $ 5.11 $ 3.14 February 7, 2018 6,175 $ 4.03 $ 4.03 $ 2.43 February 19, 2018 22,676 $ 4.41 $ 4.41 $ 2.66 Determining the fair value of share options The fair value of each grant of share options was determined by the Company using the Black-Scholes options pricing model. The total fair value of option awards in the years ended March 31, 2018, March 31, 2017 and March 31, 2016 amounted to $1,718, $1,379 and $2,054, respectively. Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected volatility . The expected volatility was based on the historical share volatilities of a selection of the Company’s publicly listed peers over a period equal to the expected terms of the options as the Company did not have a sufficient trading history to use the volatility of its own ordinary shares. Fair value of ordinary shares. Since the Company’s initial public offering in April 2014, the fair value of ordinary shares has been based on the share price of the Company’s shares on the NASDAQ Global Market immediately prior to the grant of the options concerned. Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield curve in effect at the time of grant prior to the initial public offering and 10 year U.S. Treasury Stock for awards from April 2014 onwards. Expected term. The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards. Expected dividend. According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price. A summary of the weighted-average assumptions applicable to the share options is as follows: Year ended March 31, 2018 2017 2016 Risk-free interest rate 2.34 % 1.98 % 2.26 % Expected lives (years) 6 3 3 Volatility 66.03 % 62.93 % 57.38 % Dividend yield — — — Grant date fair value (per share) $ 6.93 $ 9.12 $ 14.71 Number granted 406,480 419,682 404,327 RSU and MRSU Activity A summary of the RSUs and MRSUs in issue at March 31, 2018 is as follows: Number of RSUs or MRSUs Outstanding Weighted Average Remaining Vesting Period (Months) Period in which the target must be achieved RSUs subject to time based vesting 249,879 13 N/A RSUs subject to MosaiQ milestone vesting 260,000 N/A N/A MRSUs with vesting based on $60 share price 72,500 N/A Apr - Dec 2018 MRSUs with vesting based on $40 share price 85,000 N/A Apr - Dec 2018 MRSUs with vesting based on $22 share price 106,000 N/A Apr - Dec 2019 At March 31, 2018, 249,879 RSUs were subject to time based vesting and the weighted average remaining vesting period was 13 months. In addition, 260,000 RSUs were subject to vesting based on the achievement of various milestones relating to the development, approval and marketing of MosaiQ. Furthermore, 106,000 MRSUs were awarded on May 24, 2017, which will vest if the volume weighted average price of the Company’s ordinary shares exceeds $22 for a continuous 20 day period between April 1, 2019 and December 31, 2019. The Company determined the grant date fair value of these MRSUs using a barrier option pricing model with the same grant date fair value per share, risk free interest rate, volatility and dividend yield assumptions as the options awarded on the same date. This resulted in a grant date fair value of $3.20 per MRSU on May 24, 2017. The remainder of the MRSUs in issue at March 31, 2018 comprised 72,500 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company’s ordinary share price exceeds $60 for 20 consecutive days in this period, and 85,000 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company’s ordinary share price exceeds $40 for 20 consecutive days in this period. The fair value of the Company’s ordinary shares was $4.71 per share on March 31, 2018. As of March 31, 2018, total compensation cost related to share options and RSUs granted but not yet recognized was $3,983 net of estimated forfeitures. This cost will be amortized to expense over a weighted average remaining period of 10 months and will be adjusted for subsequent changes in estimated forfeitures. During the year ended March 31, 2018, certain modifications were made to the vesting terms of the awards held by one employee upon his retirement. The modifications had the effect of reducing the compensation expense for the year ended March 31, 2018 by $279.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. Income Taxes No provision has been made for current income taxes in any period. The statutory standard corporate income tax rate of the Company in Jersey is 0%. The principal operating subsidiaries operate in the United States, the United Kingdom and Switzerland and are subject to corporate income taxes in those countries. All these entities have trading losses available to shelter any taxable profits and accordingly, no current income taxes liabilities have been provided for. In the year ended March 31, 2018, as a result of improvements in the profitability of a subsidiary, the valuation allowances held against the deferred tax assets in that subsidiary, which principally comprised of trading losses, have been reduced resulting in the recognition of deferred tax assets of $649. A reconciliation of the income tax expense at the statutory rate to the provision for income taxes is as follows: Year ended March 31, 2018 2017 2016 Income tax expense at statutory rate $ — $ — $ — Foreign tax rate differential 4,841 1,823 (1,106 ) (Increase) decrease in valuation allowance against deferred tax assets (4,192 ) (1,823 ) 1,106 Provision for income tax $ 649 $ — $ — Significant components of deferred tax assets are as follows: March 31, 2018 March 31, 2017 Deferred tax assets: Provisions and reserves $ 1,327 $ 1,053 Net operating loss carry forwards 12,476 7,873 Gross deferred tax assets $ 13,803 $ 8,926 Fixed assets basis difference $ (284 ) $ (248 ) Gross deferred tax liabilities $ (284 ) $ (248 ) Net deferred tax asset $ 13,519 $ 8,678 Valuation allowance (12,870 ) (8,678 ) Total $ 649 $ — The balance sheet classification of net deferred tax liabilities is as follows: March 31, 2018 March 31, 2017 Net noncurrent deferred tax assets $ 649 $ — Total $ 649 $ — The Company maintains a valuation allowance on net operating losses and other deferred tax assets in jurisdictions for which it does not believe it is more-likely-than-not to realize those deferred tax assets based upon all available positive and negative evidence, including historical operating performance, carryback periods, reversal of taxable temporary differences, tax planning strategies, and earnings expectations. As of March 31, 2018, the Company has net operating loss carry forwards of approximately $139,116 and $1,789 of U.S. state net operating losses, which will be available to offset future taxable income. If not used, losses with a tax effect of approximately $12,452 will expire within five years and losses with a tax effect of $400 will expire in 2038. The remaining portion of the carry forward losses arose in jurisdictions where losses do not expire. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in tax expense. During the fiscal years ended March 31, 2018, March 31, 2017 and March 31, 2016, the Company had no amounts accrued for interest and penalties. The Company does not currently anticipate that the total amount of unrecognized tax benefits will result in material changes to its financial position within the next 12 months. The Company has evaluated its tax positions in all jurisdictions at each year end and has concluded that there are no material uncertain tax positions. The Company files separate company income tax returns in its domestic and foreign jurisdictions. All necessary income tax filings in all jurisdictions have been completed for all years up to and including March 31, 2017 and there are no ongoing tax examinations in any jurisdiction. No tax charge arose on any element of other comprehensive loss.

Pension Plans

Pension Plans	12 Months Ended
	Mar. 31, 2018
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Pension Plans	Note 11. The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents the contribution payable by the Company to the fund during the year. Defined contribution pension costs during the years ended March 31, 2018, 2017 and 2016 amounted to $1,197, $742 and $580, respectively. In addition, the Company’s Swiss subsidiary has a fully insured pension plan managed by Swiss Life. Under this plan, annual contributions are paid for each employee as determined by Swiss Life and each employee accrues pension benefits with Swiss Life. The risks of disability, death and longevity are also fully insured by Swiss Life. Swiss Life invests the pension contributions and provides a 100% capital and interest guarantee for the pension benefits. These pension arrangements are based on a contract of affiliation between the Company’s Swiss subsidiary and the Swiss Life pension foundation, which can be terminated by either party. In the event of a termination, the Company’s Swiss subsidiary would have an obligation to find alternative pension arrangements for its employees. Because there is no guarantee that the Swiss employee pension arrangements would be continued under the same conditions, there is a risk, albeit remote, that a pension obligation may fall on the Company’s Swiss subsidiary. These circumstances require that the Swiss employee pension arrangements be treated as a defined benefit plan under ASC 715 Compensation – Retirement Benefits The following provides a reconciliation of the benefit obligations, the plan assets and the funded status. Year ended March 31, 2018 March 31, 2017 Pension benefit obligation, beginning of year $ 13,318 $ 8,957 Service cost 1,601 1,353 Contributions paid by plan participants 2,627 3,483 Interest cost 110 39 Benefits paid (2,601 ) (694 ) Actuarial loss 32 591 Foreign currency translation 697 (411 ) Pension benefit obligation, end of year $ 15,784 $ 13,318 Year ended March 31, 2018 March 31, 2017 Fair value of plan assets, beginning of year $ 7,981 $ 4,455 Actual return on plan assets 78 71 Contributions paid by employer 1,110 892 Contributions paid by plan participants 2,627 3,483 Benefits paid (2,601 ) (694 ) Foreign currency translation 421 (226 ) Fair value of plan assets, end of year $ 9,616 $ 7,981 Contributions paid by plan participants include $1,958 and $2,940 of payments into the scheme on new employees joining in the years ended March 31, 2018 and March 31, 2017, respectively. Year ended March 31, 2018 March 31, 2017 Pension benefit obligation, end of year $ 15,784 $ 13,318 Fair value of plan assets, end of year 9,616 7,981 Net funding obligation, end of year $ 6,168 $ 5,337 The assumptions used to determine the pension obligation are: Year ended March 31, 2018 March 31, 2017 Price inflation 1.00 % 1.00 % Discount rate 1.00 % 0.80 % Expected return on plan assets 1.40 % 1.40 % Average rate of salary increase 1.00 % 1.00 % Each employee participating in the plan has an individual portfolio that is managed by Swiss Life under a collective arrangement. Plan assets comprise the surrender value of the portfolio of active insured scheme participants. The expected return on plan assets was determined after consideration of current and historical levels of return and discussions with Swiss Life. The discount rate is based on bond yields at March 31, 2018 and March 31, 2017 on the Swiss bond market over a fifteen to twenty-five year period. The net pension costs for the year comprises: Year ended March 31, 2018 March 31, 2017 Employer service cost $ 1,601 $ 1,353 Interest cost 110 39 Expected return on plan assets (115 ) (61 ) Amortization of prior service credit (14 ) (14 ) Amortization of net loss 188 186 Net pension cost $ 1,770 $ 1,503 The provision for pension benefit obligation recognized in other comprehensive income comprises: Year ended March 31, 2018 March 31, 2017 Net actuarial loss $ 67 $ 582 Amortization of prior service credit 14 14 Amortization of net loss (188 ) (186 ) $ (107 ) $ 410 The following benefit payments are expected to be paid in the following periods: 2019 $ 981 2020 $ 917 2021 $ 863 2022 $ 818 2023 $ 742 2024 to 2027 $ 3,518 Expected annual employer contributions to the plan in the year ending March 31, 2019 amount to $1,124.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Net Loss Per Share	Note 12. In accordance with ASC 260 Earnings Per Share The following table sets forth the computation of basic loss per ordinary share. Diluted earnings per share figures are not applicable due to losses: Year ended March 31, 2018 2017 2016 Numerator: Net loss $ (82,338 ) $ (85,069 ) $ (33,878 ) Net loss available to ordinary shareholders - basic and diluted $ (82,338 ) $ (85,069 ) $ (33,878 ) Denominator: Weighted-average shares outstanding - basic and diluted 40,839,309 28,145,472 19,558,152 Loss per share - basic and diluted $ (2.02 ) $ (3.02 ) $ (1.73 ) The following sets out the numbers of the options, RSUs (including MRSUs) and warrants to purchase ordinary shares excluded from the above computation of earnings per share for the years ended March 31, 2018, March 31, 2017 and March 31, 2016, as their inclusion would have been anti-dilutive. March 31, 2018 March 31, 2017 March 31, 2016 Ordinary shares issuable on exercise of options to purchase ordinary shares 2,096,283 1,948,917 1,589,938 Restricted share units awarded, including the multi-year performance related restricted share units 773,379 843,608 237,695 Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 111,525 111,525 Ordinary shares issuable on exercise of warrants at $9.375 per share 64,000 64,000 64,000 Ordinary shares issuable on exercise of warrants at $5.80 per share 8,414,683 — — Ordinary shares issuable on exercise of warrants at $0.01 per share 550,000 — 850,000 12,009,870 2,968,050 2,853,158

Organization and Summary of S20

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. All gains and losses realized from foreign currency transactions denominated in currencies other than the foreign subsidiary’s functional currency are included in foreign currency exchange gain (loss) as part of other income or expenses in the Consolidated Statements of Comprehensive Loss. Adjustments resulting from translating the financial statements of all foreign subsidiaries into U.S. dollars are reported as a separate component of accumulated other comprehensive loss and changes in shareholders’ deficit. The assets and liabilities of the Company’s foreign subsidiaries are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at rates approximating the weighted average rates during the period. The translation effects of inter-company loans designated as long term net investments in subsidiaries are included in accumulated other comprehensive loss.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 4, “Fair Value Measurements,” for information and related disclosures regarding our fair value measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of March 31, 2018 and 2017, all cash and cash equivalents comprised cash balances held with the banks used by the Company and its subsidiaries. At March 31, 2018 and March 31, 2017, the Company held $320 and $305 respectively in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary and $5.0 million in a cash reserve account pursuant to the indenture governing the Secured Notes. The cash reserve account is classified as a long- term asset as the indenture requires it to be maintained while the Secured Notes remain outstanding.
Short-term Investments	Short-term Investments Short-term investments represent investments in a money-market fund which is valued daily and which has no minimum notice period for withdrawals. The fund is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company records the value of its investment in the fund based on the quoted value of the fund at the balance sheet date. Unrealized gains or losses are recorded in accumulated other comprehensive loss and are transferred to the statement of comprehensive loss when they are realized.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as general and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms. The allowance for doubtful accounts at March 31, 2018 and 2017 was $93 and $103, respectively.
Concentration of Credit Risks and Other Uncertainties	Concentration of Credit Risks and Other Uncertainties The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting of foreign exchange contracts and short-term investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the foreign exchange contracts consist of large financial institutions of high credit standing. The short-term investments are invested in a fund which is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company’s main financial institutions for banking operation held all of the Company’s cash and cash equivalents as of March 31, 2018 and March 31, 2017. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of March 31, 2018 and March 31, 2017. This customer represented 51% and 59% of the accounts receivable balances, as of March 31, 2018 and March 31, 2017, respectively. The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the fiscal years ended March 31, 2018, 2017 and 2016. This customer represented 63%, 60% and 57% of total product sales for the fiscal years March 31, 2018, 2017 and 2016, respectively.
Inventory	Inventory Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of March 31, 2018 and 2017.
Property and Equipment	Property and Equipment Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows: • Land—not depreciated. • Plant, machinery and equipment—4 to 25 years; • Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by comparing the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the fiscal years ended March 31, 2018, 2017 and 2016, no impairment losses have been recorded.
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows: Customer relationships—5 years Brands associated with acquired cell lines—40 years Product licenses—10 years Other intangibles—7 years The Company reviews its intangible assets for impairment and conducts the impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. If the carrying value exceeds the Company’s estimate of future undiscounted cash flows, an impairment value is calculated as the excess of the carrying value of the asset over the Company’s estimate of its fair market value. Events or circumstances which could trigger an impairment review include a significant adverse change in the business climate, an adverse action or assessment by a regulator, unanticipated competition, significant changes in the Company’s use of acquired assets, the Company’s overall business strategy, or significant negative industry or economic trends. No impairment losses have been recorded in any of the years ended March 31, 2018, 2017 or 2016. Goodwill represents the excess of the purchase price in a business combination over the fair value of tangible and identifiable intangible assets acquired less liabilities assumed. Goodwill resulting from a business combination in 2007 has been fully impaired.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract and included in other revenues. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. Pursuant to the Umbrella Supply Agreement with Ortho-Clinical Diagnostics (“Ortho”), in June 2013, the Company executed a product attachment relating to the development of a range of rare antisera products. This product attachment was amended in August 2016. During the year ended March 31, 2017, the Company recognized the milestones of $1,300 related to the completion of the CE marking of the products for use on Ortho’s automation platforms and $800 related to the receipt of FDA approval of certain of the rare antisera products. The Company earned a milestone of $600 related to the receipt of FDA approval of the rare antisera products in the year ended March 31, 2018 and, under the terms of the amended product attachment, the Company is entitled to receive a milestone payment of $1,500 upon the updating of the FDA approvals to cover use of the products on Ortho’s automation platforms. In January 2015, the Company entered into a supply and distribution agreement with Ortho related to the commercialization and distribution of certain MosaiQ The Company has concluded that as each of these milestones require significant levels of development work to be undertaken and there was no certainty at the start of the projects that the development work would be successful, these milestones are substantive and should be accounted for under the milestone method of revenue recognition.
Research and Development	Research and Development Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. Other than materials assessed as having alternative future uses and which are recognized as prepaid expenses, the Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Comprehensive Loss. In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach for share options and a barrier option pricing model for multi-year performance based restricted share units or MRSUs, both of which require the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their awards before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to awards that will ultimately not complete their vesting requirements (forfeitures). Where modifications are made to vesting conditions, as happened during the year ended March 31, 2018 upon the retirement of Paul Cowan, the Company's former Chief Executive Officer, the Company considers the nature of the change and accounts for the change in accordance with ASC 715 Compensation – Stock Compensation
Share Warrants	Share Warrants The Company has three classes of warrants to purchase ordinary shares outstanding: (i) warrants that were issued in December 2013 and August 2015 in connection with the entry into and subsequent amendment of the Company’s then existing secured term loan facility; (ii) warrants issued in October 2017 as part of a private placement of ordinary shares and warrants, and (iii) pre-funded warrants issued in October 2017 as part of the private placement of ordinary shares and warrants. None of these warrants contain any obligation to transfer value and, as such, the issuance of these warrants has been recorded in additional paid in capital as part of shareholders’ equity. The Company also issued warrants to purchase ordinary shares at the time of its initial public offering. These warrants were recorded as a liability because the underlying terms of the warrants contained provisions that may have obligated the Company to transfer value in certain circumstances. The warrants were recorded at fair value upon issuance and were subject to re-measurement to fair value at each balance sheet date, with any change in fair value recognized as component of other income (expense), net on the Consolidated Statements of Comprehensive Loss. These warrants expired on October 26, 2015 and were either exercised prior to that date or expired on that date. As a result, at March 31, 2018 and March 31, 2017, there was no longer any liability related to these warrants.
Leases	Leases At the inception of each lease, the Company reviews the terms of the lease in accordance with ASC 840 Leases Rentals relating to operating leases are expensed over the life of the lease.
Derivative Financial Instruments	Derivative Financial Instruments In the normal course of business, the Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations. The Company’s policy is to mitigate the effect of these exchange rate fluctuations on certain foreign currency denominated business exposures. The Company has a policy that allows the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on forecasted revenue denominated in foreign currencies. The Company carries derivative financial instruments (derivatives) on the balance sheet at their fair values. The Company does not use derivatives for trading or speculative purposes. The Company does not believe that it is exposed to more than a nominal amount of credit risk in its foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. To hedge foreign currency risks, the Company uses foreign currency exchange forward contracts, where possible and prudent. These forward contracts are valued using standard valuation formulas with assumptions about future foreign currency exchange rates derived from existing exchange rates, interest rates, and other market factors. The Company considers its most current forecast in determining the level of foreign currency denominated revenue to hedge as cash flow hedges. The Company combines these forecasts with historical trends to establish the portion of its expected volume to be hedged. The revenue and expenses are hedged and designated as cash flow hedges to protect the Company from exposures to fluctuations in foreign currency exchange rates. If the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, the related hedge gains and losses on the cash flow hedge are reclassified from accumulated other comprehensive loss to the consolidated statement of comprehensive loss at that time.
Income Taxes	Income Taxes The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements, but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. Therefore, the Company provides a valuation allowance to the extent that is more likely than not that it will generate sufficient taxable income in future periods to realize the benefit of its deferred tax assets.
Pension Obligation	Pension Obligation The Company maintains a pension plan covering employees in Switzerland pursuant to the requirements of Swiss pension law. Certain aspects of the plan require that it be accounted for as a defined benefit plan pursuant to ASC 715 Compensation – Retirement Benefits The Company uses an actuarial valuation to determine its pension benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Details of the assumptions used to determine the net funded status are set out in Note 11. The Company’s pension plan assets are assigned to their respective levels in the fair value hierarchy in accordance with the valuation principles described in the ‘‘Fair Value of Financial Instruments’’ section above.
Debt Issuance Costs and Royalty Rights	Debt Issuance Costs and Royalty Rights The Company follows the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. The royalty rights agreements entered into with subscribers to the issue of the Secured Notes are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 “ Debt”
Adoption of New Accounting Standards	Adoption of New Accounting Standards The FASB issued ASU 2014-09, Revenue from Contracts with Customers Recent Accounting Pronouncements Not Yet Adopted The FASB issued ASU 2016-02, Leases The FASB issued ASU 2016-18, Statement of Cash Flows - Restricted Cash The FASB issued ASU 2017-07, Compensation - Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost The FASB issued ASU 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	March 31, 2018 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,758 $ (2,758 ) $ — — Brands associated with acquired cell lines 569 (150 ) 419 29.5 years Product licenses 954 (459 ) 495 5.2 years Other intangibles 179 (179 ) — — Total $ 4,460 $ (3,546 ) $ 914 16.3 years March 31, 2017 Gross Carrying Amount Accumulated Amortization Net Amount Weighted Average Remaining Useful Customer relationships $ 2,458 $ (2,458 ) $ — — Brands associated with acquired cell lines 507 (121 ) 386 30.4 years Product licenses 716 (333 ) 383 5.4 years Other intangibles 160 (160 ) — — Total $ 3,841 $ (3,072 ) $ 769 17.9 years
Schedule of Future Amortization Expense	Total future amortization expense for intangible assets that have definite lives, based upon the Company’s existing intangible assets and their current estimated useful lives as of March 31, 2018, is estimated as follows: 2019 $ 110 2020 110 2021 110 2022 110 2023 110 Thereafter 364 Total $ 914

Debt (Tables)

Debt (Tables)	12 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt comprises: March 31, 2018 March 31, 2017 Total debt $ 84,000 $ 84,000 Less current portion — — Long-term debt $ 84,000 $ 84,000 Deferred debt costs and royalty liability, net of amortization 1,063 (3,296 ) $ 85,063 $ 80,704
Schedule of Outstanding Debt	The outstanding debt at March 31, 2018 falls due for repayment as follows: Within 1 year $ — Between 1 and 2 years 13,440 Between 2 and 3 years 14,280 Between 3 and 4 years 16,800 Between 4 and 5 years 18,480 After 5 years 21,000 Total debt $ 84,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis	The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy: March 31, 2018 Level 1 Level 2 Level 3 Total Assets: Pension plan assets (1) $ — $ 9,616 $ — $ 9,616 Short-term investments (2) 5,669 — — 5,669 Foreign currency forward contracts (3) — 118 — 118 Total assets measured at fair value $ 5,669 $ 9,734 $ — $ 15,403 March 31, 2018 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts (3) $ — $ 64 $ — $ 64 Total liabilities measured at fair value $ — $ 64 $ — $ 64 March 31, 2017 Level 1 Level 2 Level 3 Total Assets: Pension plan assets (1) $ — $ 7,981 $ — $ 7,981 Short-term investments (2) 16,057 — — 16,057 Total assets measured at fair value $ 16,057 $ 7,981 $ — $ 24,038 March 31, 2017 Level 1 Level 2 Level 3 Total Liabilities: Foreign currency forward contracts (3) $ — $ 252 $ — $ 252 Total liabilities measured at fair value $ — $ 252 $ — $ 252 (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the Swiss Life collective investment fund. (2) The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”. (3) The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.

Consolidated Balance Sheet De24

Consolidated Balance Sheet Detail (Tables)	12 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Inventory	The following table summarizes inventory by category for the periods presented: March 31, 2018 March 31, 2017 Raw materials $ 10,024 $ 8,993 Work in progress 4,226 3,260 Finished goods 2,028 1,383 Total inventories $ 16,278 $ 13,636
Summary of Property and Equipment	The following table summarizes property and equipment by categories for the periods presented: March 31, 2018 March 31, 2017 Land $ — $ 1,286 Plant and equipment 51,912 44,797 Leasehold improvements 34,611 32,343 Total property and equipment 86,523 78,426 Less: accumulated depreciation (26,367 ) (14,896 ) Total property and equipment, net $ 60,156 $ 63,530
Summary of Accrued Compensation and Benefits	Accrued compensation and benefits consist of the following: March 31, 2018 March 31, 2017 Salary and related benefits $ 455 $ 403 Accrued vacation 504 413 Accrued payroll taxes 1,353 325 Accrued incentive payments 3,000 2,500 Total accrued compensation and benefits $ 5,312 $ 3,641
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: March 31, 2018 March 31, 2017 Accrued legal and professional fees $ 280 $ 449 Accrued interest 4,612 4,640 Goods received not invoiced 1,272 932 Accrued capital expenditure 3,309 1,387 Accrued development expenditure — 4,187 Other accrued expenses 5,867 1,914 Total accrued expenses and other current liabilities $ 15,340 $ 13,509

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Future Rentals on Non-Cancelable Operating Leases	The following is a schedule by years of minimum future rentals on non-cancelable operating leases as of March 31, 2018: 2019 $ 3,828 2020 3,477 2021 1,889 2022 1,923 2023 1,976 Thereafter 80,919 Total minimum future lease payments $ 94,012
Schedule of Future Annual Repayments on Capital Leases	The following is a schedule of future annual repayments on capital leases as of March 31, 2018: 2019 $ 515 2020 510 2021 392 2022 321 2023 199 Thereafter — Total minimum future lease payments $ 1,937
Schedule of Purchase Obligations	The following is a schedule by years of purchase obligations as of March 31, 2018: 2019 $ 15,083 2020 9,200 2021 22,155 2022 18,267 2023 8,591 Thereafter 9,767 Total minimum future purchase obligations $ 83,063

Geographic Information (Tables)

Geographic Information (Tables)	12 Months Ended
	Mar. 31, 2018
Geographic Areas Revenues And Long Lived Assets [Abstract]
Schedule of Revenue From Customer By Geographic Area	The following table represents revenue attributed to countries based on the location of the customer: Year ended March 31, 2018 2017 2016 Revenue: United States $ 12,917 $ 11,432 $ 8,879 United Kingdom 980 1,003 1,437 France 5,608 4,733 3,376 Japan 3,335 3,141 2,836 Other foreign countries (1) 1,892 1,918 1,994 $ 24,732 $ 22,227 $ 18,522 (1) No individual country represented more than 10% of the respective totals.
Consolidated Property and Equipment, Net by Country	The table below lists the Company’s property and equipment, net of accumulated depreciation, by country. With the exception of property and equipment, the Company does not identify or allocate its assets by geographic area: March 31, 2018 March 31, 2017 Long-lived assets: United Kingdom $ 24,141 $ 20,925 Switzerland 36,009 42,596 United States 6 9 $ 60,156 $ 63,530

Ordinary and Preference Shares

Ordinary and Preference Shares (Tables)	12 Months Ended
	Mar. 31, 2018
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Summary of Shares Issued and Outstanding	The Company’s issued and outstanding preference shares consist of the following: Shares Issued and Outstanding Liquidation amount per share March 31, 2018 March 31, 2017 March 31, 2018 March 31, 2017 7% Cumulative Redeemable Preference shares 666,665 666,665 $ 27.50 $ 25.92 Total 666,665 666,665
Ordinary Shares [Member]
Class Of Stock [Line Items]
Summary of Shares Issued and Outstanding	The Company’s issued and outstanding ordinary shares consist of the following: Shares Issued and Outstanding March 31, 2018 March 31, 2017 Par value Ordinary shares 45,646,424 29,567,698 $ — Total 45,646,424 29,567,698 $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Share Option Activity	The following table summarizes share option activity: Number of Share Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual (Months) Outstanding — March 31, 2015 1,208,118 $ 5.58 103 Granted 404,327 14.71 120 Exercised (8,712 ) 4.72 — Forfeited (13,795 ) 10.25 — Outstanding — March 31, 2016 1,589,938 $ 7.86 96 Granted 419,682 9.12 120 Exercised (8,483 ) 1.44 — Forfeited (52,220 ) 12.50 — Outstanding — March 31, 2017 1,948,917 $ 8.04 90 Granted 406,480 6.93 120 Exercised (36,240 ) 3.07 — Forfeited (222,874 ) 9.16 — Outstanding — March 31, 2018 2,096,283 $ 7.79 84 Exercisable —March 31, 2018 1,368,870 $ 7.27 74
Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value	The following table summarizes the options granted in the year ended March 31, 2018 with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any: Grant Date Number of Options Granted Exercise Price Ordinary Shares Fair Value Per Share at Grant Date Per Share Intrinsic Value of Options May 24, 2017 305,525 $ 7.58 $ 7.58 $ 4.62 August 9, 2017 4,000 $ 5.41 $ 5.41 $ 3.34 October 31, 2017 67,179 $ 5.21 $ 5.21 $ 3.20 November 1, 2017 925 $ 5.11 $ 5.11 $ 3.14 February 7, 2018 6,175 $ 4.03 $ 4.03 $ 2.43 February 19, 2018 22,676 $ 4.41 $ 4.41 $ 2.66
Summary of Weighted-Average Assumptions to Share Options Issued	A summary of the weighted-average assumptions applicable to the share options is as follows: Year ended March 31, 2018 2017 2016 Risk-free interest rate 2.34 % 1.98 % 2.26 % Expected lives (years) 6 3 3 Volatility 66.03 % 62.93 % 57.38 % Dividend yield — — — Grant date fair value (per share) $ 6.93 $ 9.12 $ 14.71 Number granted 406,480 419,682 404,327
Summary of RSUs and MRSUs	A summary of the RSUs and MRSUs in issue at March 31, 2018 is as follows: Number of RSUs or MRSUs Outstanding Weighted Average Remaining Vesting Period (Months) Period in which the target must be achieved RSUs subject to time based vesting 249,879 13 N/A RSUs subject to MosaiQ milestone vesting 260,000 N/A N/A MRSUs with vesting based on $60 share price 72,500 N/A Apr - Dec 2018 MRSUs with vesting based on $40 share price 85,000 N/A Apr - Dec 2018 MRSUs with vesting based on $22 share price 106,000 N/A Apr - Dec 2019

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Reconciliation of the Income Tax Expenses at the Statutory Rate	A reconciliation of the income tax expense at the statutory rate to the provision for income taxes is as follows: Year ended March 31, 2018 2017 2016 Income tax expense at statutory rate $ — $ — $ — Foreign tax rate differential 4,841 1,823 (1,106 ) (Increase) decrease in valuation allowance against deferred tax assets (4,192 ) (1,823 ) 1,106 Provision for income tax $ 649 $ — $ —
Components of Deferred Tax Assets	Significant components of deferred tax assets are as follows: March 31, 2018 March 31, 2017 Deferred tax assets: Provisions and reserves $ 1,327 $ 1,053 Net operating loss carry forwards 12,476 7,873 Gross deferred tax assets $ 13,803 $ 8,926 Fixed assets basis difference $ (284 ) $ (248 ) Gross deferred tax liabilities $ (284 ) $ (248 ) Net deferred tax asset $ 13,519 $ 8,678 Valuation allowance (12,870 ) (8,678 ) Total $ 649 $ —
Classification of Net Deferred Tax Liabilities	The balance sheet classification of net deferred tax liabilities is as follows: March 31, 2018 March 31, 2017 Net noncurrent deferred tax assets $ 649 $ — Total $ 649 $ —

Pension Plans (Tables)

Pension Plans (Tables)	12 Months Ended
	Mar. 31, 2018
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Reconciliation of Benefit Obligations	Year ended March 31, 2018 March 31, 2017 Pension benefit obligation, beginning of year $ 13,318 $ 8,957 Service cost 1,601 1,353 Contributions paid by plan participants 2,627 3,483 Interest cost 110 39 Benefits paid (2,601 ) (694 ) Actuarial loss 32 591 Foreign currency translation 697 (411 ) Pension benefit obligation, end of year $ 15,784 $ 13,318
Reconciliation of Plan Assets	Year ended March 31, 2018 March 31, 2017 Fair value of plan assets, beginning of year $ 7,981 $ 4,455 Actual return on plan assets 78 71 Contributions paid by employer 1,110 892 Contributions paid by plan participants 2,627 3,483 Benefits paid (2,601 ) (694 ) Foreign currency translation 421 (226 ) Fair value of plan assets, end of year $ 9,616 $ 7,981
Reconciliation of Funded Status	Contributions paid by plan participants include $1,958 and $2,940 of payments into the scheme on new employees joining in the years ended March 31, 2018 and March 31, 2017, respectively. Year ended March 31, 2018 March 31, 2017 Pension benefit obligation, end of year $ 15,784 $ 13,318 Fair value of plan assets, end of year 9,616 7,981 Net funding obligation, end of year $ 6,168 $ 5,337
Assumptions Used to Determine Pension Obligation	The assumptions used to determine the pension obligation are: Year ended March 31, 2018 March 31, 2017 Price inflation 1.00 % 1.00 % Discount rate 1.00 % 0.80 % Expected return on plan assets 1.40 % 1.40 % Average rate of salary increase 1.00 % 1.00 %
Schedule of Net Pension Costs	The net pension costs for the year comprises: Year ended March 31, 2018 March 31, 2017 Employer service cost $ 1,601 $ 1,353 Interest cost 110 39 Expected return on plan assets (115 ) (61 ) Amortization of prior service credit (14 ) (14 ) Amortization of net loss 188 186 Net pension cost $ 1,770 $ 1,503
Schedule of Provision for Pension Benefit Obligation Recognized in Other Comprehensive Income	The provision for pension benefit obligation recognized in other comprehensive income comprises: Year ended March 31, 2018 March 31, 2017 Net actuarial loss $ 67 $ 582 Amortization of prior service credit 14 14 Amortization of net loss (188 ) (186 ) $ (107 ) $ 410
Schedule of Benefit Payments Expected to be Paid	The following benefit payments are expected to be paid in the following periods: 2019 $ 981 2020 $ 917 2021 $ 863 2022 $ 818 2023 $ 742 2024 to 2027 $ 3,518

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Computation of Earnings Per Share Basic and Diluted	The following table sets forth the computation of basic loss per ordinary share. Diluted earnings per share figures are not applicable due to losses: Year ended March 31, 2018 2017 2016 Numerator: Net loss $ (82,338 ) $ (85,069 ) $ (33,878 ) Net loss available to ordinary shareholders - basic and diluted $ (82,338 ) $ (85,069 ) $ (33,878 ) Denominator: Weighted-average shares outstanding - basic and diluted 40,839,309 28,145,472 19,558,152 Loss per share - basic and diluted $ (2.02 ) $ (3.02 ) $ (1.73 )
Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share	The following sets out the numbers of the options, RSUs (including MRSUs) and warrants to purchase ordinary shares excluded from the above computation of earnings per share for the years ended March 31, 2018, March 31, 2017 and March 31, 2016, as their inclusion would have been anti-dilutive. March 31, 2018 March 31, 2017 March 31, 2016 Ordinary shares issuable on exercise of options to purchase ordinary shares 2,096,283 1,948,917 1,589,938 Restricted share units awarded, including the multi-year performance related restricted share units 773,379 843,608 237,695 Ordinary shares issuable on exercise of warrants at $16.14 per share 111,525 111,525 111,525 Ordinary shares issuable on exercise of warrants at $9.375 per share 64,000 64,000 64,000 Ordinary shares issuable on exercise of warrants at $5.80 per share 8,414,683 — — Ordinary shares issuable on exercise of warrants at $0.01 per share 550,000 — 850,000 12,009,870 2,968,050 2,853,158

Organization and Summary of S32

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	Oct. 24, 2017USD ($)$ / sharesshares	Apr. 10, 2017USD ($)$ / sharesshares	Mar. 31, 2018USD ($)Customer$ / sharesshares	Mar. 31, 2017USD ($)Customershares	Mar. 31, 2016USD ($)Customershares	Mar. 31, 2017USD ($)Customer	Jul. 31, 2018$ / shares	Oct. 14, 2016USD ($)
Significant Accounting Policies [Line Items]
Gross proceeds of the private placement	$ 40,200,000					$ 70,600,000
Gross proceeds from public offerings of shares and issuances of ordinary shares upon exercise of warrants						132,800,000
Exercise price of warrants | $ / shares			$ 5.80
Expected proceeds receivable from exercise of warrants			$ 48,800,000
Warrant exercisable date			Jul. 31, 2018
Accumulated deficit			$ (275,639,000)	$ (193,301,000)		(193,301,000)
Cash holdings and short-term investments			25,500,000
Proceeds from equity private placement			49,000,000
Restricted cash			320,000	305,000		305,000
Allowance for doubtful accounts			$ 93,000	$ 103,000		$ 103,000
Number of customer represent 10% or more of accounts receivable | Customer			1	1		1
Number of customer represent 10% or more of product sales | Customer			1	1	1	1
Stock-based compensation cost included in inventory			$ 0	$ 0		$ 0
Property and equipment impairment losses			0	0	$ 0
Impairment losses			$ 0	0	$ 0
Class of warrants description			The Company has three classes of warrants to purchase ordinary shares outstanding: (i) warrants that were issued in December 2013 and August 2015 in connection with the entry into and subsequent amendment of the Company’s then existing secured term loan facility; (ii) warrants issued in October 2017 as part of a private placement of ordinary shares and warrants, and (iii) pre-funded warrants issued in October 2017 as part of the private placement of ordinary shares and warrants.
Ortho's [Member]
Significant Accounting Policies [Line Items]
Milestone revenue recognized				1,300,000
Rare Antisera Products [Member]
Significant Accounting Policies [Line Items]
Milestone revenue recognized			$ 600,000	$ 800,000
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization over estimated useful life			5 years
Brands Associated with Acquired Cell Lines [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization over estimated useful life			40 years
Product Licenses [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization over estimated useful life			10 years
Other Intangibles [Member]
Significant Accounting Policies [Line Items]
Intangible assets amortization over estimated useful life			7 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Plant, machinery and equipment useful life			4 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Plant, machinery and equipment useful life			25 years
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage			51.00%	59.00%
Customer Concentration Risk [Member] | Sales [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage			63.00%	60.00%	57.00%
Scenario, Forecast [Member]
Significant Accounting Policies [Line Items]
Exercise price of warrants | $ / shares							$ 5.80
Amendment Products [Member]
Significant Accounting Policies [Line Items]
Milestone amount receivable upon fulfillment of achievement			$ 1,500,000
Private Placement [Member]
Significant Accounting Policies [Line Items]
Issue of shares, shares | shares	7,864,683
Subscription price per share | $ / shares	$ 4.64
Warrants price per warrant | $ / shares	$ 0.125
Issued warrants to acquire ordinary shares | shares	8,414,683
Exercise price of warrants | $ / shares	$ 5.80
Private Placement [Member] | Pre-Funded Warrants [Member]
Significant Accounting Policies [Line Items]
Warrants price per warrant | $ / shares	$ 4.755
Issued warrants to acquire ordinary shares | shares	550,000
Exercise price of warrants | $ / shares	$ 0.01
Ordinary Shares [Member]
Significant Accounting Policies [Line Items]
Issue of shares, shares | shares		8,050,000	15,914,683	3,270,000	4,444,445
Share issue price | $ / shares		$ 6
Gross proceeds from issuance of ordinary shares		$ 48,300,000
Senior Secured Notes Due 2023 [Member]
Significant Accounting Policies [Line Items]
Gross proceeds from issuance of debt						$ 84,000,000
Debt instrument, interest rate			12.00%	12.00%		12.00%
Credit facility, available borrowing capacity			$ 36,000,000
Balance in cash reserve account held by collateral agent			$ 5,000,000	$ 5,000,000		$ 5,000,000		$ 5,000,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 4,460	$ 3,841
Accumulated Amortization	(3,546)	(3,072)
Net Carrying Amount	$ 914	$ 769
Weighted Average Remaining Useful Life	16 years 3 months 18 days	17 years 10 months 24 days
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,758	$ 2,458
Accumulated Amortization	(2,758)	(2,458)
Brands Associated with Acquired Cell Lines [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	569	507
Accumulated Amortization	(150)	(121)
Net Carrying Amount	$ 419	$ 386
Weighted Average Remaining Useful Life	29 years 6 months	30 years 4 months 24 days
Product Licenses [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 954	$ 716
Accumulated Amortization	(459)	(333)
Net Carrying Amount	$ 495	$ 383
Weighted Average Remaining Useful Life	5 years 2 months 12 days	5 years 4 months 24 days
Other Intangibles [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 179	$ 160
Accumulated Amortization	$ (179)	$ (160)

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 94	$ 73	$ 89

Intangible Assets - Schedule 35

Intangible Assets - Schedule of Future Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
2,019	$ 110
2,020	110
2,021	110
2,022	110
2,023	110
Thereafter	364
Net Carrying Amount	$ 914	$ 769

Debt - Schedule of Long-Term De

Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Debt Disclosure [Abstract]
Total debt	$ 84,000	$ 84,000
Long-term debt	84,000	84,000
Deferred debt costs and royalty liability, net of amortization	1,063	(3,296)
Long-term debt, less current portion	$ 85,063	$ 80,704

Debt - Additional Information (

Debt - Additional Information (Detail) - Senior Secured Notes Due 2023 [Member] - USD ($)	Oct. 14, 2016	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Debt instrument, interest rate		12.00%	12.00%
Debt instrument, issuance date		Oct. 14, 2016	Oct. 14, 2016
Aggregate principal amount of notes issued	$ 84,000,000
Debt instrument, restrictive covenants		The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent. Upon the occurrence of a Change of Control, subject to certain conditions, or certain Asset Sales (each, as defined in the indenture), holders of the Secured Notes may require the Company to repurchase for cash all or part of their Secured Notes at a repurchase price equal to 101% or 100%, respectively, of the principal amount of the Secured Notes to be repurchased, plus accrued and unpaid interest to the date of repurchase.
Debt instrument, percentage of repurchase price on change of control		101.00%
Debt instrument, percentage of repurchase price		100.00%
Aggregate principal additional amount of notes to be issued	36,000,000
Payment to cash reserve account held by collateral agent	$ 5,000,000	$ 5,000,000	$ 5,000,000
Debt instrument, unused/additional borrowing capacity		The Company issued $84 million aggregate principal amount of the Secured Notes on October 14, 2016 and, so long as no event of default has occurred, the Company will issue an additional $36 million aggregate principal amount of the Secured Notes upon public announcement of field trial results for the MosaiQ IH Microarray that demonstrates greater than 99% concordance for the detection of blood group antigens and greater than 95% concordance for the detection of blood group antibodies when compared to predicate technologies for a pre-defined set of blood group antigens and antibodies.
Debt instrument date of first required payment, principal	Apr. 15, 2019
MosaiQ [Member]
Debt Instrument [Line Items]
Debt instrument subscribers right to receive payment as percentage of net MosaiQ sales	2.00%
Estimated amount under royalty agreement		$ 41,800,000	$ 40,400,000
Maximum [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes issued	$ 120,000,000

Debt - Schedule of Outstanding

Debt - Schedule of Outstanding Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Long-term Debt, Rolling Maturity [Abstract]
Between 1 and 2 years	$ 13,440
Between 2 and 3 years	14,280
Between 3 and 4 years	16,800
Between 4 and 5 years	18,480
After 5 years	21,000
Total debt	$ 84,000	$ 84,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands		Mar. 31, 2018	Mar. 31, 2017
Liabilities:
Total liabilities measured at fair value		$ 64	$ 252
Recurring [Member]
Assets:
Total assets measured at fair value		15,403	24,038
Liabilities:
Total liabilities measured at fair value		64	252
Recurring [Member] | Foreign currency forward contracts [Member]
Assets:
Total assets measured at fair value	[1]	118
Liabilities:
Total liabilities measured at fair value	[1]	64	252
Recurring [Member] | Pension plan assets [Member]
Assets:
Total assets measured at fair value	[2]	9,616	7,981
Recurring [Member] | Short-term Investments [Member]
Assets:
Total assets measured at fair value	[3]	5,669	16,057
Recurring [Member] | Level 1 [Member]
Assets:
Total assets measured at fair value		5,669	16,057
Recurring [Member] | Level 1 [Member] | Short-term Investments [Member]
Assets:
Total assets measured at fair value	[3]	5,669	16,057
Recurring [Member] | Level 2 [Member]
Assets:
Total assets measured at fair value		9,734	7,981
Liabilities:
Total liabilities measured at fair value		64	252
Recurring [Member] | Level 2 [Member] | Foreign currency forward contracts [Member]
Assets:
Total assets measured at fair value	[1]	118
Liabilities:
Total liabilities measured at fair value	[1]	64	252
Recurring [Member] | Level 2 [Member] | Pension plan assets [Member]
Assets:
Total assets measured at fair value	[2]	$ 9,616	$ 7,981
[1]	The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.
[2]	The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the Swiss Life collective investment fund.
[3]	The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. See Note 1, “Summary of Significant Accounting Policies – Short-term Investments”.

Consolidated Balance Sheet De40

Consolidated Balance Sheet Detail - Summary of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 10,024	$ 8,993
Work in progress	4,226	3,260
Finished goods	2,028	1,383
Total inventories	$ 16,278	$ 13,636

Consolidated Balance Sheet De41

Consolidated Balance Sheet Detail - Additional Information (Detail) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Raw materials	$ 10,024,000	$ 8,993,000
Work in progress	4,226,000	3,260,000
Finished products	2,028,000	1,383,000
Biocampus Facility [Member]
Value added tax liability	2,905,000	0
MosaiQ Project [Member]
Raw materials	8,441,000	7,659,000
Work in progress	1,528,000	$ 1,415,000
Finished products	$ 389,000

Consolidated Balance Sheet De42

Consolidated Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Property Plant And Equipment [Line Items]
Total property and equipment	$ 86,523	$ 78,426
Less: accumulated depreciation	(26,367)	(14,896)
Total property and equipment, net	60,156	63,530
Land [Member]
Property Plant And Equipment [Line Items]
Total property and equipment		1,286
Plant and Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	51,912	44,797
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 34,611	$ 32,343

Consolidated Balance Sheet De43

Consolidated Balance Sheet Detail - Summary of Property and Equipment (Parenthetical) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expenses	$ 10,311	$ 9,375	$ 2,856

Consolidated Balance Sheet De44

Consolidated Balance Sheet Detail - Summary of Accrued Compensation and Benefits (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Compensation Related Costs [Abstract]
Salary and related benefits	$ 455	$ 403
Accrued vacation	504	413
Accrued payroll taxes	1,353	325
Accrued incentive payments	3,000	2,500
Total accrued compensation and benefits	$ 5,312	$ 3,641

Consolidated Balance Sheet De45

Consolidated Balance Sheet Detail - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Payables And Accruals [Abstract]
Accrued legal and professional fees	$ 280	$ 449
Accrued interest	4,612	4,640
Goods received not invoiced	1,272	932
Accrued capital expenditure	3,309	1,387
Accrued development expenditure		4,187
Other accrued expenses	5,867	1,914
Total accrued expenses and other current liabilities	$ 15,340	$ 13,509

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) £ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)Contracts$ / £	Mar. 31, 2018GBP (£)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2008GBP (£)
Commitments And Contingencies [Line Items]
Expiry date of operating leases	2,052	2,052
Operating leases, rent expense	$ 3,063,000		$ 2,928,000	$ 2,923,000
Capital leased assets, gross cost	3,130,000		1,928,000
Capital leases, balance sheet, assets by major class, net	2,810,000		1,663,000
Research and development grant funding from Scottish Enterprise | £					£ 1,791
Claims from grant | £		£ 1,790
Total liabilities measured at fair value	64,000		252,000
Gain (loss) on ineffective foreign currency derivatives recorded in earnings, net	$ 0		$ 0	$ 0
Through June 2018 [Member]
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts	3
Forward exchange contracts sold	$ 500,000
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £	1.2990
Total assets measured at fair value	$ 118,000
July 2018 through December 2018 [Member]
Commitments And Contingencies [Line Items]
Number of forward exchange contracts | Contracts	6
Forward exchange contracts sold	$ 500,000
Forward exchange contracts exchange rate pounds sterling to US dollar | $ / £	1.4315
Biocampus Facility [Member]
Commitments And Contingencies [Line Items]
Sale leaseback transaction net cash proceeds	$ 19,741,000
Sale leaseback transaction deferred gain	473,000
Rental deposit	$ 5,043,000

Commitments and Contingencies47

Commitments and Contingencies - Schedule of Minimum Future Rentals on Non-cancelable Operating Leases (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,019	$ 3,828
2,020	3,477
2,021	1,889
2,022	1,923
2,023	1,976
Thereafter	80,919
Total minimum future lease payments	$ 94,012

Commitments and Contingencies48

Commitments and Contingencies - Schedule of Future Annual Repayments on Capital Leases (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,019	$ 515
2,020	510
2,021	392
2,022	321
2,023	199
Total minimum future lease payments	$ 1,937

Commitments and Contingencies49

Commitments and Contingencies - Schedule of Purchase Obligations (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,019	$ 15,083
2,020	9,200
2,021	22,155
2,022	18,267
2,023	8,591
Thereafter	9,767
Total minimum future purchase obligations	$ 83,063

Geographic Information - Additi

Geographic Information - Additional Information (Detail) $ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)Segment	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)
Geographic Areas Long Lived Assets [Abstract]
Number of business segments | Segment	1
Foreign exchange gains | $	$ 2,366	$ 2,853	$ 4,120

Geographic Information - Schedu

Geographic Information - Schedule of Revenue From Customer By Geographic Area (Detail) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		$ 24,732	$ 22,227	$ 18,522
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		12,917	11,432	8,879
United Kingdom [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		980	1,003	1,437
France [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		5,608	4,733	3,376
Japan [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue		3,335	3,141	2,836
Other foreign countries [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenue	[1]	$ 1,892	$ 1,918	$ 1,994
[1]	No individual country represented more than 10% of the respective totals.

Geographic Information - Consol

Geographic Information - Consolidated Property and Equipment, Net by Country (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	$ 60,156	$ 63,530
United Kingdom [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	24,141	20,925
Switzerland [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	36,009	42,596
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Property and equipment, net	$ 6	$ 9

Ordinary and Preference Share53

Ordinary and Preference Shares - Summary of Shares Issued and Outstanding (Detail) - $ / shares	Mar. 31, 2018	Mar. 31, 2017
Class Of Stock [Line Items]
Ordinary shares, shares issued	45,646,424	29,567,698
Ordinary shares, shares outstanding	45,646,424	29,567,698
Ordinary shares, par value
Preference shares, shares issued	666,665	666,665
Preference shares, shares outstanding	666,665	666,665
Ordinary Shares [Member]
Class Of Stock [Line Items]
Ordinary shares, shares issued	45,646,424	29,567,698
Ordinary shares, shares outstanding	45,646,424	29,567,698
Ordinary shares, par value
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Preference shares, shares issued	666,665	666,665
Preference shares, shares outstanding	666,665	666,665
Liquidation amount per share	$ 27.50	$ 25.92

Ordinary and Preference Share54

Ordinary and Preference Shares - Summary of Shares Issued and Outstanding (Parenthetical) (Detail)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Dividend percentage	7.00%	7.00%

Ordinary and Preference Share55

Ordinary and Preference Shares - Additional Information (Detail)	Jan. 29, 2015$ / shares
7% Cumulative Redeemable Preference Shares [Member]
Class Of Stock [Line Items]
Subscriptions price, per share	$ 22.50

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018USD ($)d$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Oct. 28, 2016shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense | $	$ 4,156	$ 4,221	$ 2,004
Number of Options Granted	406,480	419,682	404,327
Total fair value of stock options granted | $	$ 1,718	$ 1,379	$ 2,054
Risk-free interest rate, Description	Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield curve in effect at the time of grant prior to the initial public offering and 10 year U.S. Treasury Stock for awards from April 2014 onwards.
Grant date fair value (per share) | $ / shares	$ 6.93	$ 9.12	$ 14.71
Total compensation cost not yet recognized related to share options and RSUs | $	$ 3,983
Total compensation cost not yet recognized related to share options, RSUs, weighted average remaining amortization period	10 months
Reducing the compensation expense | $	$ 279
Ordinary Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of ordinary shares per share | $ / shares	$ 4.71
Restricted Stock Units (RSUs) [Member] | Time Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	249,879
Weighted average remaining vesting period	13 months
Restricted Stock Units (RSUs) [Member] | Milestone Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	260,000
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $22 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	106,000
Consecutive trading days in which price must exceed threshold | d	20
Period in which the target must be achieved, start date	Apr. 1, 2019
Period in which the target must be achieved, end date	Dec. 31, 2019
Grant date fair value (per share) | $ / shares	$ 3.20
Award vesting description	106,000 MRSUs were awarded on May 24, 2017, which will vest if the volume weighted average price of the Company’s ordinary shares exceeds $22 for a continuous 20 day period between April 1, 2019 and December 31, 2019.
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $60 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	72,500
Consecutive trading days in which price must exceed threshold | d	20
Period in which the target must be achieved, start date	Apr. 1, 2018
Period in which the target must be achieved, end date	Dec. 31, 2018
Award vesting description	72,500 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company’s ordinary share price exceeds $60 for 20 consecutive days in this period, and 85,000 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company’s ordinary share price exceeds $40 for 20 consecutive days in this period.
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $40 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units outstanding	85,000
Consecutive trading days in which price must exceed threshold | d	20
Period in which the target must be achieved, start date	Apr. 1, 2018
Period in which the target must be achieved, end date	Dec. 31, 2018
Award vesting description	85,000 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company’s ordinary share price exceeds $40 for 20 consecutive days in this period.
Minimum [Member] | Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $22 Share Price [Member] | Ordinary Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares | $ / shares	$ 22
Minimum [Member] | Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $60 Share Price [Member] | Ordinary Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares | $ / shares	60
Minimum [Member] | Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $40 Share Price [Member] | Ordinary Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares | $ / shares	$ 40
Employee Stock Option [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Employee Stock Option [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2012 Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares upon each option exercised	1
Maximum number of shares authorized for grant	839,509
Vesting period	3 years
Contractual life	10 years
Options exercisable percentage description	Options were not exercisable before the Company became a public company and all outstanding options become exercisable in the event of an acquisition of 75% or more of the share capital of the Company by a third party. No further awards will be granted under the 2012 Option Plan.
Number of Options Granted	0
2014 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ordinary shares reserved for issuance	1,500,000
Increase in number of shares reserved for future issuance				750,000

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share Option Activity (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Share Options Outstanding, Beginning Balance	1,948,917	1,589,938	1,208,118
Number of Share Options Outstanding, Granted	406,480	419,682	404,327
Number of Share Options Outstanding, Exercised	(36,240)	(8,483)	(8,712)
Number of Share Options Outstanding, Forfeited	(222,874)	(52,220)	(13,795)
Number of Share Options Outstanding, Ending Balance	2,096,283	1,948,917	1,589,938	1,208,118
Number of Share Options Outstanding, Exercisable	1,368,870
Weighted-Average Exercise Price, Beginning Balance	$ 8.04	$ 7.86	$ 5.58
Weighted-Average Exercise Price, Granted	6.93	9.12	14.71
Weighted-Average Exercise Price, Exercised	3.07	1.44	4.72
Weighted-Average Exercise Price, Forfeited	9.16	12.50	10.25
Weighted-Average Exercise Price, Ending Balance	7.79	$ 8.04	$ 7.86	$ 5.58
Weighted-Average Exercise Price, Exercisable	$ 7.27
Weighted-Average Remaining Contractual Life, Outstanding	84 months	90 months	96 months	103 months
Weighted-Average Remaining Contractual Life, Granted	120 months	120 months	120 months
Weighted-Average Remaining Contractual Life, Exercisable	74 months

Share-Based Compensation - Su58

Share-Based Compensation - Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Granted	406,480	419,682	404,327
Exercise Price	$ 6.93	$ 9.12	$ 14.71
Ordinary Shares Fair Value Per Share at Grant Date	$ 6.93	$ 9.12	$ 14.71
May 24, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	May 24, 2017
Number of Options Granted	305,525
Exercise Price	$ 7.58
Ordinary Shares Fair Value Per Share at Grant Date	7.58
Per Share Intrinsic Value of Options	$ 4.62
August 9, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Aug. 9, 2017
Number of Options Granted	4,000
Exercise Price	$ 5.41
Ordinary Shares Fair Value Per Share at Grant Date	5.41
Per Share Intrinsic Value of Options	$ 3.34
October 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Oct. 31, 2017
Number of Options Granted	67,179
Exercise Price	$ 5.21
Ordinary Shares Fair Value Per Share at Grant Date	5.21
Per Share Intrinsic Value of Options	$ 3.20
November 1, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Nov. 1, 2017
Number of Options Granted	925
Exercise Price	$ 5.11
Ordinary Shares Fair Value Per Share at Grant Date	5.11
Per Share Intrinsic Value of Options	$ 3.14
February 7, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Feb. 7, 2018
Number of Options Granted	6,175
Exercise Price	$ 4.03
Ordinary Shares Fair Value Per Share at Grant Date	4.03
Per Share Intrinsic Value of Options	$ 2.43
February 19, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant Date	Feb. 19, 2018
Number of Options Granted	22,676
Exercise Price	$ 4.41
Ordinary Shares Fair Value Per Share at Grant Date	4.41
Per Share Intrinsic Value of Options	$ 2.66

Share-Based Compensation - Su59

Share-Based Compensation - Summary of Weighted-Average Assumptions to Share Options Issued (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rate	2.34%	1.98%	2.26%
Expected lives (years)	6 years	3 years	3 years
Volatility	66.03%	62.93%	57.38%
Grant date fair value (per share)	$ 6.93	$ 9.12	$ 14.71
Number of Share Options Outstanding, Granted	406,480	419,682	404,327

Share-Based Compensation - Su60

Share-Based Compensation - Summary of RSUs and MRSUs (Detail)	12 Months Ended
	Mar. 31, 2018shares
Restricted Stock Units (RSUs) [Member] | Time Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs or MRSUs Outstanding	249,879
Weighted Average Remaining Vesting Period (Months)	13 months
Restricted Stock Units (RSUs) [Member] | Milestone Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs or MRSUs Outstanding	260,000
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $60 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs or MRSUs Outstanding	72,500
Period in which the target must be achieved, start date	Apr. 1, 2018
Period in which the target must be achieved, end date	Dec. 31, 2018
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $40 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs or MRSUs Outstanding	85,000
Period in which the target must be achieved, start date	Apr. 1, 2018
Period in which the target must be achieved, end date	Dec. 31, 2018
Multi Year Performance Based Restricted Stock Units [Member] | Vesting Based on $22 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of RSUs or MRSUs Outstanding	106,000
Period in which the target must be achieved, start date	Apr. 1, 2019
Period in which the target must be achieved, end date	Dec. 31, 2019

Share-Based Compensation - Su61

Share-Based Compensation - Summary of RSUs and MRSUs (Detail) (Parenthetical) - Multi Year Performance Based Restricted Stock Units [Member] - Minimum [Member] - Ordinary Shares [Member]	Mar. 31, 2018$ / shares
Vesting Based on $60 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares	$ 60
Vesting Based on $40 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares	40
Vesting Based on $22 Share Price [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average price of shares	$ 22

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Income Taxes [Line items]
Statutory standard corporate income tax rate	0.00%
Deferred tax assets	$ 649,000
Net operating loss carry forwards	139,116,000
Net operating loss carry forwards, subject to expiration	$ 12,452,000
Net operating loss carry forwards expiration period	5 years
Net operating loss carry forwards expiration year	2,038
Unrecognized tax benefits, Income tax penalties and interest accrued	$ 0	$ 0	$ 0
Tax charge	0
Tax Year 2038 [Member]
Income Taxes [Line items]
Net operating loss carry forwards, subject to expiration	400,000
U.S. state [Member]
Income Taxes [Line items]
Net operating loss carry forwards	$ 1,789,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of the Income Tax Expenses at the Statutory Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Foreign tax rate differential	$ 4,841	$ 1,823	$ (1,106)
(Increase) decrease in valuation allowance against deferred tax assets	(4,192)	$ (1,823)	$ 1,106
Provision for income tax	$ 649

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017
Deferred tax assets:
Provisions and reserves	$ 1,327	$ 1,053
Net operating loss carry forwards	12,476	7,873
Gross deferred tax assets	13,803	8,926
Fixed assets basis difference	(284)	(248)
Gross deferred tax liabilities	(284)	(248)
Net deferred tax asset	13,519	8,678
Valuation allowance	(12,870)	$ (8,678)
Total	$ 649

Income Taxes - Classification o

Income Taxes - Classification of Net Deferred Tax Liabilities (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Income Tax Disclosure [Abstract]
Net noncurrent deferred tax assets	$ 649
Total	$ 649

Pension Plans - Additional Info

Pension Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Contribution Plan Disclosure [Line Items]
Defined contribution pension cost		$ 1,197	$ 742	$ 580
Percentage of capital and interest guaranteed by Swiss Life		100.00%
Accumulated pension obligation		$ 15,784	13,318	8,957
Plan assets		9,616	7,981	$ 4,455
Net funded status		6,168	5,337
Contributions paid by plan participants		2,627	3,483
Contributions paid or to be paid by employer		$ 1,110	$ 892
Scenario, Forecast [Member]
Defined Contribution Plan Disclosure [Line Items]
Contributions paid or to be paid by employer	$ 1,124
Minimum [Member]
Defined Contribution Plan Disclosure [Line Items]
Bond yield maturity period		15 years	15 years
Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Bond yield maturity period		25 years	25 years
New Employees [Member]
Defined Contribution Plan Disclosure [Line Items]
Contributions paid by plan participants		$ 1,958	$ 2,940

Pension Plans - Reconciliation

Pension Plans - Reconciliation of Benefit Obligations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Pension benefit obligation, beginning of year	$ 13,318	$ 8,957
Service cost	1,601	1,353
Contributions paid by plan participants	2,627	3,483
Interest cost	110	39
Benefits paid	(2,601)	(694)
Actuarial loss	32	591
Foreign currency translation	697	(411)
Pension benefit obligation, end of year	$ 15,784	$ 13,318

Pension Plans - Reconciliatio68

Pension Plans - Reconciliation of Plan Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Fair value of plan assets, beginning of year	$ 7,981	$ 4,455
Actual return on plan assets	78	71
Contributions paid by employer	1,110	892
Contributions paid by plan participants	2,627	3,483
Benefits paid	(2,601)	(694)
Foreign currency translation	421	(226)
Fair value of plan assets, end of year	$ 9,616	$ 7,981

Pension Plans - Reconciliatio69

Pension Plans - Reconciliation of Funded Status (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Pension benefit obligation, end of year	$ 15,784	$ 13,318	$ 8,957
Fair value of plan assets, end of year	9,616	7,981	$ 4,455
Net funding obligation, end of year	$ 6,168	$ 5,337

Pension Plans - Assumptions Use

Pension Plans - Assumptions Used to Determine Pension Obligation (Detail)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Price inflation	1.00%	1.00%
Discount rate	1.00%	0.80%
Expected return on plan assets	1.40%	1.40%
Average rate of salary increase	1.00%	1.00%

Pension Plans - Schedule of Net

Pension Plans - Schedule of Net Pension Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Employer service cost	$ 1,601	$ 1,353
Interest cost	110	39
Expected return on plan assets	(115)	(61)
Amortization of prior service credit	(14)	(14)
Amortization of net loss	188	186
Net pension cost	$ 1,770	$ 1,503

Pension Plans - Schedule of Pro

Pension Plans - Schedule of Provision for Pension Benefit Obligation Recognized in Other Comprehensive Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
Net actuarial loss	$ 67	$ 582
Amortization of prior service credit	14	14
Amortization of net loss	(188)	(186)
Provision for pension benefit obligation	$ (107)	$ 410	$ 4,502

Pension Plans - Schedule of Ben

Pension Plans - Schedule of Benefit Payments Expected to be Paid (Detail) $ in Thousands	Mar. 31, 2017USD ($)
Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]
2,019	$ 981
2,020	917
2,021	863
2,022	818
2,023	742
2024 to 2027	$ 3,518

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Earnings Per Share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss	$ (82,338)	$ (85,069)	$ (33,878)
Net loss available to ordinary shareholders - basic and diluted	$ (82,338)	$ (85,069)	$ (33,878)
Denominator:
Weighted-average shares outstanding - basic and diluted	40,839,309	28,145,472	19,558,152
Loss per share - basic and diluted	$ (2.02)	$ (3.02)	$ (1.73)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) - shares	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	12,009,870	2,968,050	2,853,158
Exercise Of Options To Purchase Ordinary Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	2,096,283	1,948,917	1,589,938
Restricted Share Units Awarded, Including Multi-Year Performance
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	773,379	843,608	237,695
Exercise Of Warrants At $16.14 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	111,525	111,525	111,525
Exercise Of Warrants At $9.37 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	64,000	64,000	64,000
Exercise Of Warrants At $5.80 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	8,414,683
Exercise Of Warrants At $0.01 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares issuable excluded from computation of earnings per share	550,000		850,000

Net Loss Per Share - Summary 76

Net Loss Per Share - Summary of Number of Ordinary Shares Excluded from Computation of Earnings Per Share (Detail) (Parenthetical) - $ / shares	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	$ 5.80
Exercise Of Warrants At $16.14 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	16.14	$ 16.14	$ 16.14
Exercise Of Warrants At $9.37 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	9.375	$ 9.375	9.375
Exercise Of Warrants At $5.80 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	5.80
Exercise Of Warrants At $0.01 Per Share
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Exercise price of warrants per share	$ 0.01		$ 0.01